Effect of Remimazolam on Postoperative Delirium Among Patients Undergoing Deep Hypothemic Cardiopulmonary Bypass

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054365

Enrollment

Unknown

Registered

2021-12-15

Start date

2021-12-01

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiopulmonary Bypass Related Brain Injury

Interventions

Experimental group:Remazolam tosylate 0.3-0.5 mg/kg/h by pump during cardiopulmonary bypass

Control group:Inject propofol 1-3 mg/kg/h during cardiopulmonary bypass

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with type A aortic dissection requiring deep hypothemic cardiopulmonary bypass.

Exclusion criteria

Exclusion criteria: 1. Patients with preoperative delirium; 3. Patients who are allergic to remazolam tosylate; 3. Patients with a history of drug abuse; 4. Patients who are taking psychotropic drugs.

Design outcomes

Primary

Measure	Time frame
incidence of postoperative in-hospital delirium;	—

Secondary

Measure	Time frame
delirium duration;cognitive decline;30-day mortality;ICU length of stay;hospital length of stay;	—

Countries

China

Contacts

Public ContactLiang Beiwei

The First Affiliated Hospital of Guangxi Medical University

461016302@qq.com+86 13517882902

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026